Eli Lilly to acquire AtaiBeckley for up to $3.8 billion to bolster its psychedelic drug portfolio for mental health treatments.
Eli Lilly will acquire AtaiBeckley, a clinical-stage developer of psychedelic medications, for up to $3.8 billion. The move signals a growing trend of pharmaceutical giants embracing psychedelics as viable alternatives for treating various mental health conditions. AtaiBeckley’s lead asset, BPL-003, is a synthetic form of 5-MeO-DMT designed to treat treatment-resistant depression. The acquisition follows an executive order from the administration in April to fast-track Food and Drug Administration reviews for these drugs. While psychedelics were once federally outlawed as having no medical benefit, they are now undergoing rigorous clinical trials to treat anxiety, PTSD, and addiction. For example, Definium Therapeutics recently reported positive Phase 3 results for an LSD-based drug, while Compass Pathways is preparing to launch a synthetic psilocybin drug by 2027. Industry analysts suggest that while the market is large, it is not a "winner-take-all" space. Multiple psychedelic drugs are expected to succeed as mainstream treatments, potentially offering a paradigm shift in psychiatry by "rewiring" the brain's communication patterns.